S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Price, News & Analysis

$3.87
-0.04 (-1.02%)
(As of 04/19/2024 ET)
Today's Range
$3.79
$3.96
50-Day Range
$3.87
$5.46
52-Week Range
$3.79
$8.05
Volume
978,622 shs
Average Volume
984,477 shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.86

AbCellera Biologics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
309.7% Upside
$15.86 Price Target
Short Interest
Bearish
11.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.54mentions of AbCellera Biologics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.66) to ($0.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.26 out of 5 stars

Medical Sector

734th out of 908 stocks

Pharmaceutical Preparations Industry

323rd out of 404 stocks

ABCL stock logo

About AbCellera Biologics Stock (NASDAQ:ABCL)

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Stock Price History

ABCL Stock News Headlines

AbCellera Biologics (NASDAQ:ABCL) Hits New 1-Year Low at $3.84
AbCellera Biologics Inc. (ABCL)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
The 7 Best Penny Stocks to Buy in Q2 2024
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
AbCellera: Victim Of Its Own Success
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
AbCellera Announces Resignation of Board Member
ABCL Mar 2024 4.000 call
ABCL Mar 2024 5.000 call
Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Q4 2023 Abcellera Biologics Inc Earnings Call
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
586
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.86
High Stock Price Target
$24.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+309.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-146,400,000.00
Net Margins
-384.99%
Pretax Margin
-457.67%

Debt

Sales & Book Value

Annual Sales
$38.03 million
Book Value
$3.97 per share

Miscellaneous

Free Float
197,774,000
Market Cap
$1.13 billion
Optionable
Optionable
Beta
0.36
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 49)
    CEO, President & Chairperson
    Comp: $711.47k
  • Mr. Andrew Booth M.B.A.Mr. Andrew Booth M.B.A. (Age 50)
    Chief Financial Officer
    Comp: $642.42k
  • Dr. Veronique Lecault Ph.D. (Age 39)
    COO & Director
    Comp: $645.07k
  • Mr. Tryn T. Stimart Esq. (Age 54)
    J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer
    Comp: $644.4k
  • Mr. Neil Aubuchon B.A. (Age 53)
    M.B.A., Chief Commercial Officer
    Comp: $684.81k
  • Marcie Thiessen CPA
    CGA, Senior Director of Finance & Accounting
  • Dr. Ester Falconer Ph.D. (Age 49)
    Chief Technology Officer
  • Kathleen Reid B.A.
    Head of Corporate Communications
  • Graham Craig M.Sc.
    Director of Corporate Development
  • Mr. Murray McCutcheon Ph.D.
    Senior Vice President of Partnering

ABCL Stock Analysis - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price target for 2024?

7 equities research analysts have issued 1-year target prices for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $24.00. On average, they expect the company's share price to reach $15.86 in the next twelve months. This suggests a possible upside of 309.7% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2024?

AbCellera Biologics' stock was trading at $5.71 at the start of the year. Since then, ABCL stock has decreased by 32.2% and is now trading at $3.87.
View the best growth stocks for 2024 here
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ABCL earnings forecast
.

How can I listen to AbCellera Biologics' earnings call?

AbCellera Biologics will be holding an earnings conference call on Tuesday, May 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) posted its earnings results on Tuesday, February, 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The business earned $9.18 million during the quarter, compared to the consensus estimate of $9.58 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 12.36% and a negative net margin of 384.99%.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?

AbCellera Biologics (ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TrueMark Investments LLC (0.04%) and Pacifica Partners Inc. (0.00%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends
.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABCL) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners